A Clinical study to evaluate the efficacy and safety of nutraceutical formulation in neurodegenerative diseases linked to cognitive impairment

CSIR0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年4月3日

研究概览

暂无简介。

•1.Mild and moderate subjective symptoms of memory impairment.
•2.Age of patient :50-80 years.
•3.A previous diagnosis of early dementia or MCI with a score of >9 and <23 on the mini-mental state examination
•4.The ability and willingness to provide informed consent.

•1.A screening MMSE score of <9(indicating severe memory impairment.)
•2.Known neuropsychiatric conditions.
•3.Uncontrolled hypertension or diabetes mellitus.
•4.Drug dependence or addiction.
•5.Use of alcohol, psychotropic drugs or alternative
•medicines for memory.
•6.Subject with concurrent Hepatic dysfunction.
•7.Subjects suffering from major systemic illness necessitating long term drug use (R.A.,T.B.)
•8.Any other condition which the investigator thinks may compromise the safety.
•9.Subjects with established diagnosis of CAD requiring any procedure in next 6 months -angioplasty or bypass surgery or any other clinically significant cardiovascular disease.
•10.Already known hypersensitivity to any interventional drug.
•11.Patients who have participated in any clinical trial during past 6 months.

发起方

CSIR